Journal article
Epidemiology, biology and therapy of Merkel cell carcinoma: conclusions from the EU project IMMOMEC
JC Becker, A Stang, A Hausen, N Fischer, JA DeCaprio, RW Tothill, R Lyngaa, UK Hansen, C Ritter, P Nghiem, CK Bichakjian, S Ugurel, D Schrama
Cancer Immunology Immunotherapy | SPRINGER | Published : 2018
Abstract
Merkel cell carcinoma (MCC) is a highly aggressive, often lethal neuroendocrine cancer. Its carcinogenesis may be either caused by the clonal integration of the Merkel cell polyomavirus into the host genome or by UV-induced mutations. Notably, virally-encoded oncoproteins and UV-induced mutations affect comparable signaling pathways such as RB restriction of cell cycle progression or p53 inactivation. Despite its low incidence, MCC recently received much attention based on its exquisite immunogenicity and the resulting major success of immune modulating therapies. Here, we summarize current knowledge on epidemiology, biology and therapy of MCC as conclusion of the project ‘Immune Modulating ..
View full abstractGrants
Awarded by National Cancer Institute
Funding Acknowledgements
J. C. Becker is funded by the European Commission Grant Agreement # 277,775/IMMOMEC, the BMBF 03VP01062/CTCelect, the Hiege Stiftung, and the German Cancer Consortium (DKTK). A. Stang receives a Grant from the German Federal Ministry of Education and Science (BMBF), Grant Number 01ER1305. J. A. DeCaprio was supported in part by US Public Health Service Grants R01CA63113, R01CA173023, P01CA050661, the DFCI Helen Pappas Merkel Cell Research Fund and the Claudia Adams Barr Program in Cancer Research. P. Nghiem was supported in part by US Public Health Service grants K24-CA139052, RO1-CA176841, and the UW MCC Gift Fund.